Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care

Table 2 Sociodemographic and clinical characteristics

Groups	Inadequate response	Remission	Total	P value
Number of patients, %	N = 965 (42.7%)	N = 1,295 (57.3%)	N = 2,260	P value
Mean age, years	61.0 (15.1)	57.1 (16.4)	58.8 (15.9)	<0.001
Ranges: 18–44 years	13.7%	24.6%	19.9%	<0.001
45–64 years	46.1%	42.6%	44.1%	<0.001
65–74 years	18.1%	13.8%	15.7%	<0.001
> 74 years	22.1%	19.0%	20.3%	<0.001
Gender, female	76.8%	71.9%	74.0%	0.009
Occupational status, retired	63.1%	47.0%	53.9%	<0.001
Mean number of comorbidities	5.3 (3.5)	4.1 (3.3)	4.6 (3.4)	<0.001
Mean RUBs	2.7 (0.9)	2.4 (1.1)	2.5 (1.1)	<0.001
RUB-1	17.1%	23.4%	20.7%	<0.001
RUB-2	9.3%	18.4%	14.5%	<0.001
RUB-3	59.5%	49.5%	53.8%	<0.001
RUB-4	12.3%	7.1%	9.3%	<0.001
RUB-5	1.8%	1.5%	1.6%	<0,001
Mean Charlson index	0.4 (0.7)	0.3 (0.8)	0.4 (0.7)	NS
Associated comorbidities
Arterial hypertension	39.0%	30.6%	34.2%	<0.001
Diabetes mellitus	17.1%	12.9%	14.7%	0.005
Dyslipidemia	49.7%	39.1%	43.6%	<0.001
Obesity	22.3%	18.7%	20.2%	0.035
Active smoking	22.9%	25.9%	24.6%	NS
Alcoholism	4.2%	4.4%	4.3%	NS
Ischemic heart disease	7.0%	3.7%	5.1%	<0.001
Cerebrovascular events	10.6%	7.7%	8.9%	0.019
Cardiovascular events	15.4%	10.4%	12.6%	<0.001
Organ insufficiency	11.5%	11.1%	11.3%	NS
Bronchial asthma.	8.8%	5.6%	7.0%	<0.001
COPD	4.2%	3.2%	3.6%	NS
Neuropathies	2.4%	1.5%	1.9%	NS
Dementia (all types)	4.9%	3.2%	3.9%	0.032
Organic psychosis	3.5%	2.9%	3.1%	NS
Malignant tumors	10.3%	7.1%	8.5%	0.008
Fibromyalgia	28.9%	22.4%	25.2%	<0.001
Time since MDD onset, years	4.8 (3.8)	3.5 (3.6)	4.1 (3.7)	<0.001
New, incident cases (N = 738)	23.3%	38.7%	32.2%	<0.001
Prevalent cases (N = 1,522)	76.7%	61.3%	67.8%	<0.001

RUBs: resource utilization bands (morbidity burden of patients); COPD: chronic obstructive pulmonary disease; MDD: major depressive disorder; values are given as percentage or mean (standard deviation); NS: not significant.
Patients were considered to be in remission when they had a Hamilton Depression Rating Scale total score ≤ 7 points after at least 8 weeks of AD treatment in adequate doses [24, 25].

ISSN: 1744-859X